Anemia Clinical Trials

Find Anemia Clinical Trials Near You

Efficacy and Safety of Pegmolesatide in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI): a Multi-center, Prospective, Open-label, Randomized Parallel Controlled Trial

Status: Recruiting
Location: See all (24) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

For patients with renal anemia treated with hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), there is a clinical need of switching to long-acting and safe medications. Pegmolesatide, a polyethylene glycol (PEG)-conjugated erythropoiesis-stimulating peptide, is a long-acting erythropoiesis-stimulating agent (ESA) with sustained activity. It was approved for marketing by the National Medical Products Administration (NMPA) in June 2023. Phase III clinical trials have demonstrated its efficacy and safety in dialysis patients with renal anemia who were previously treated with recombinant human erythropoietin (rHuEPO). However, there are currently no data regarding the efficacy and safety of switching from HIF-PHIs to pegmolesatide, and there is a lack of standard for the dose conversion. This study is a multi-center, prospective, open-label, randomized parallel-controlled clinical trial, planning to enroll 96 patients. All enrolled patients will receive 12 weeks of treatment and be followed up for 16 weeks.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:

• Age between 18-75 years, regardless of gender;

• Body weight ≥ 45 kg, and body mass index (BMI) ≥ 18.5 kg/m²;

• Diagnosis of chronic renal failure, and having undergone a stable regimen of peritoneal dialysis or hemodialysis for at least 12 weeks prior to enrollment (with stable hemofiltration at a frequency of every 2 or 4 weeks if applicable). Stable dialysis frequency and no plans to change the dialysis modality during the trial;

• An up to standard dialysis adequacy testing result before randomization: spKt/V ≥ 1.2 for hemodialysis, Kt/V ≥ 1.7 for peritoneal dialysis;

• Roxadustat dose ≤ 360 mg/week within 4 weeks before randomization, with stable dose; \[Stable dose is defined as: (the maximum weekly dose within 4 weeks before randomization - the average weekly dose within 4 weeks before randomization) ÷ the maximum weekly dose within 4 weeks before randomization ≤ 30%\];

• Two pre-dialysis HB test values within 4 weeks before randomization of 8.0 - 12.0 g/dl, with an absolute difference between the two Hb values ≤ 1.3 g/dl, and an interval of ≥ 7 days between the two HB tests;

• Serum ferritin level ≥ 100 μg/L and transferrin saturation (TAST) ≥ 20% at the time of testing before randomization, serum folate ≥ the lower limit of normal, and vitamin B12 ≥ the lower limit of normal;

• Understanding of the study procedures and voluntary signing of the written informed consent form.

Locations
Other Locations
China
The First Affiliated Hospital of Baotou Medical College
NOT_YET_RECRUITING
Baotou
Beijing Hospital
NOT_YET_RECRUITING
Beijing
Changsha Central Hospital
NOT_YET_RECRUITING
Changsha
Guangdong Provincial People's Hospital
NOT_YET_RECRUITING
Guangzhou
The First Affiliated Hospital of Guangzhou Medical University
NOT_YET_RECRUITING
Guangzhou
Hangzhou Xiaoshan First People's Hospital
NOT_YET_RECRUITING
Hangzhou
The First Affiliated Hospital of Shandong First Medical University
NOT_YET_RECRUITING
Jinan
Jingmen Central Hospital
NOT_YET_RECRUITING
Jingmen
Longyan First Hospital
NOT_YET_RECRUITING
Longyan
Meizhou People's Hospital
NOT_YET_RECRUITING
Meizhou
Nantong First People's Hospital
NOT_YET_RECRUITING
Nantong
The Affiliated People's Hospital of Ningbo University
NOT_YET_RECRUITING
Ningbo
The First Affiliated Hospital of Shantou University Medical College
NOT_YET_RECRUITING
Shantou
Yuebei People's Hospital
NOT_YET_RECRUITING
Shaoguan
The First Hospital of China Medical University
NOT_YET_RECRUITING
Shenyang
CNPG Dongfeng General Hospital
NOT_YET_RECRUITING
Shiyan
Tianjin First Center Hospital
NOT_YET_RECRUITING
Tianjin
Rui'an People's Hospital
NOT_YET_RECRUITING
Wenzhou
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITING
Wuhan
Wuhan Fourth Hospital
NOT_YET_RECRUITING
Wuhan
Yibin First People's Hospital
NOT_YET_RECRUITING
Yibin
Zhangzhou Municipal Hospital of Fujian Province
NOT_YET_RECRUITING
Zhangzhou
Zhongshan Hospital of Traditional Chinese Medicine
NOT_YET_RECRUITING
Zhongshan
Affiliated Hospital of Zunyi Medical University
NOT_YET_RECRUITING
Zunyi
Contact Information
Primary
Xueqing Yu
yuxueqing@gdph.org.cn
+86-20-83827812
Backup
Zhiming ye
yezhiming@gdph.org.cn
138 2616 1678
Time Frame
Start Date: 2025-09-08
Estimated Completion Date: 2027-12
Participants
Target number of participants: 96
Treatments
Experimental: Arm A1: Pegmolesatide 2mg SC
All patients in low-dose Roxadustat cohort randomised into this group will receive pegmolesatide 2mg subcutaneously once every 4 weeks.
Experimental: Arm A2: Pegmolesatide 4mg SC
All patients in low-dose Roxadustat cohort randomised into this group will receive pegmolesatide 4mg subcutaneously once every 4 weeks.
Experimental: Arm B1: Pegmolesatide 4mg SC
All patients in high-dose Roxadustat cohort randomised into this group will receive pegmolesatide 4mg subcutaneously once every 4 weeks.
Experimental: Arm B2: Pegmolesatide 6mg SC
All patients in high-dose Roxadustat cohort randomised into this group will receive pegmolesatide 6mg subcutaneously once every 4 weeks.
Related Therapeutic Areas
Sponsors
Leads: Guangdong Provincial People's Hospital

This content was sourced from clinicaltrials.gov